cbdMD, Inc. (NYSEAMERICAN:YCBD – Get Free Report)’s stock price dropped 1.6% during trading on Thursday. The stock traded as low as $0.3622 and last traded at $0.3728. Approximately 74,629 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 89,154 shares. The stock had previously closed at $0.3789.
Wall Street Analyst Weigh In
Separately, Maxim Group downgraded cbdMD from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.
Check Out Our Latest Stock Analysis on YCBD
cbdMD Stock Performance
cbdMD (NYSEAMERICAN:YCBD – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). The firm had revenue of $5.55 million during the quarter, compared to the consensus estimate of $5.69 million. cbdMD had a negative return on equity of 34.26% and a negative net margin of 13.80%.
cbdMD Company Profile
cbdMD, Inc (NYSE American: YCBD) is a consumer health and wellness company that develops, markets and sells hemp-derived cannabinoid products. Its offerings have included cannabidiol (CBD) oils and tinctures, gummies and other ingestible products, capsules, creams and lotions, as well as products formulated for sleep, recovery and general wellness.
The company also markets CBD products for pets and has expanded its portfolio to include additional cannabinoid-based and functional wellness products.
Further Reading
- Five stocks we like better than cbdMD
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.
